Filtered By:
Drug: Sensipar
Nutrition: Calcium
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 206 results found since Jan 2013.
Fine-tuned continuous renal replacement therapy with calcium-free dialysate to manage severe hypercalcemia refractory to medical and intermittent hemodialysis
AbstractMalignancy-related hypercalcemia is a leading cause of hypercalcemia among hospitalized patients that carries poor prognosis. Parathyroid carcinoma is a rare form of primary hyperparathyroidism that may be associated with PTH dependent hypercalcemia. Severe hypercalcemia is life-threatening and may require management in an intensive care unit by means of medical therapy consisting of volume expansion, loop diuretics, cinacalcet, calcitonin and bisphosphonates. Renal replacement therapy such as intermittent hemodialysis has been successfully used among patients with severe hypercalcemia who become refractory to medi...
Source: European Journal of Medical Research - June 8, 2022 Category: Research Source Type: research
A systematic review of the pharmacotherapy of secondary hyperparathyroidism (SHPT) in grades 3-5 Chronic Kidney Disease (CKD)
CONCLUSIONS: Calcifediol ER, paricalcitol, and cinacalcet significantly decreased the iPTH level in the patients under study. Paricalcitol increased the serum calcium concentration the most of all the drugs under analysis. It is noteworthy that only cinacalcet does not carry the risk of hypercalcemia.PMID:35049000 | DOI:10.26355/eurrev_202201_27773
Source: European Review for Medical and Pharmacological Sciences - January 20, 2022 Category: Drugs & Pharmacology Authors: M Miedziaszczyk I Idasiak-Piechocka O W Wi śniewski K Lacka Source Type: research
The efficacy and safety of medical and surgical therapy in patients with primary hyperparathyroidism: a systematic review and meta ‐analysis of randomized controlled trials
This article is protected by copyright. All rights reserved.
Source: Journal of Bone and Mineral Research - August 22, 2022 Category: Orthopaedics Authors: Zhikang Ye,
Shonni J. Silverberg,
Ashwini Sreekanta,
Kyle Tong,
Ying Wang,
Yaping Chang,
Mengmeng Zhang,
Gordon Guyatt,
Wimonchat Tangamornsuksun,
Yi Zhang,
Veena Manja,
Layla Bakaa,
Rachel J. Couban,
Maria Luisa Brandi,
Bart Clarke,
Aliya Tags: Task Force Source Type: research
The use of cinacalcet after pediatric renal transplantation: an international CERTAIN Registry analysis
ConclusionsThis pilot study suggests that cinacalcet as off-label therapy for SHPT after pediatric RTx is efficacious in controlling post-transplant SHPT with acceptable tolerability. Continuing cinacalcet even with normal PTH can lead to dangerous life-threatening hypocalcemia. Therefore, at each subsequent visit, the need to continue cinacalcet must be assessed.
Source: Pediatric Nephrology - July 27, 2020 Category: Urology & Nephrology Source Type: research
A systematic review of the pharmacotherapy of secondary hyperparathyroidism (SHPT) in grades 3-5 Chronic Kidney Disease (CKD)
CONCLUSIONS: Calcifediol ER, paricalcitol, and cinacalcet significantly decreased the iPTH level in the patients under study. Paricalcitol increased the serum calcium concentration the most of all the drugs under analysis. It is noteworthy that only cinacalcet does not carry the risk of hypercalcemia.PMID:35049000 | DOI:10.26355/eurrev_202201_27773
Source: Pharmacological Reviews - January 20, 2022 Category: Drugs & Pharmacology Authors: M Miedziaszczyk I Idasiak-Piechocka O W Wi śniewski K Lacka Source Type: research
Management of Primary Hyperparathyroidism With Severe Hypercalcemia During the COVID-19 Pandemic
This article presents a literature review and discussion of the pharmacologic management of PHPT and severe hypercalcemia, which can be used as a temporary measure during the COVID-19 pandemic until parathyroidectomy can be performed safely.METHODS: This narrative review was conducted by searching literature on the PubMed, Medline, and Google Scholar databases using the terms primary hyperparathyroidism, hypercalcemia, cinacalcet, bisphosphonates, denosumab, vitamin D, raloxifene, hormone replacement therapy, coronavirus, and COVID-19.FINDINGS: Appropriate monitoring and remote medical follow-up of these patients are essen...
Source: Clinical Therapeutics - March 23, 2021 Category: Drugs & Pharmacology Authors: Eman M Alfadhli Source Type: research
Cinacalcet for Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: A Meta-Analysis of Randomized Controlled Trials
Conclusions: Use of cinacalcet in dialysis patients improves several CKD-MBD-related surrogate markers. However, the benefit on all-cause mortalities was not demonstrated.Nephron
Source: Nephron - March 7, 2018 Category: Urology & Nephrology Source Type: research
